TARS
Tarsus Pharmaceuticals, Inc.
$61.21
-4.30%
2026-05-08
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Key Fundamentals
Forward P/E
21.41
EPS (TTM)
$-1.11
ROE
-23.4%
Revenue Growth (YoY)
128.4%
Profit Margin
-14.7%
Debt/Equity
24.18
Price/Book
7.77
Beta
0.53
Market Cap
$2.70B
Avg Volume (10D)
705K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$80.00
60D Low
$59.00
Avg Volume
565K
Latest Close
$61.21
Get breakout alerts for TARS
Sign up for Breakout Scanner to receive daily notifications when TARS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Tarsus Pharmaceuticals, Inc. (TARS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors TARS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. TARS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.